Oral direct thrombin inhibition for anticoagulation in coronary artery disease - Focus on the ESTEEM trial

European Heart Journal, Supplement

Volumn 6, Issue B, 2004, Pages

  Wallentin, L ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulation; Coronary arterial disease; ESTEEM; Myocardial infarction; Oral direct thrombin inhibitors; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; LIVER ENZYME; PLACEBO; THROMBIN INHIBITOR; XIMELAGATRAN;

ANGINA PECTORIS; ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LIVER TOXICITY; LONG TERM CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 1942520428     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehjsup.2004.01.015     Document Type: Review

References (32)

1. Patel VB, Topol EJ. The pathogenesis and spectrum of acute coronary syndromes: from plaque formation to thrombosis. Cleve Clin J Med 1999;66:561-71.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
3. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 2002;39:187-96.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
5. Van Aken H, Bode C, Darius H et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost 2001;7:195-204.
6. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
7. Warkentin TE. Heparin-induced thrombocytopenia. Curr Hematol Rep 2002;1:63-72.
8. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
9. Kontny F. Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. Am J Cardiol 1997;80:55E-60E.
10. Ardissino D, Merlini PA, Bauer KA et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 2003;102:2731-5.
11. Granger CB, Miller JM, Bovill EG et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.
12. Van Aken H, Bode C, Darius H et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost 2001;7:195-204.
13. Theroux P, Waters D, Lam J et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-5.
14. Weitz JI, Hudoba M, Massel D et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
15. Weitz JI. A novel approach to thrombin inhibition. Thromb Res 2003;109(Suppl 1):S17-22.
16. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000;12(Suppl F):27F-32F.
17. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002;57:751-8.
18. Gustafsson D, Nystrom J, Carlsson S et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-81.
19. Eriksson H, Eriksson UG, Frison L et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999;81:358-63.
20. Eriksson UG, Bredberg U, Hoffmann KJ et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003;31:294-305.
21. Johansson LC, Andersson M, Fager G et al. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003;42:475-84.
22. Johansson LC, Frison L, Logren U et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:381-92.
23. Sarich TC, Teng R, Peters GR et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003;42:485-92.
24. Bredberg E, Andersson TB, Frison L et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003;42:765-77.
25. Eriksson BI, Bergqvist D, Kalebo P et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
26. Francis CW, Davidson BL, Berkowitz SD et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-55.
27. Glynn O. The express study: preliminary results. Int J Clin Pract 2003;57:57-9.
28. Olsson SB. Executive steering committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8.
29. Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97.
30. Kontny F. Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. Am J Cardiol 1997;80:55E-60E.
31. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
32. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.